12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Deals

Champions Oncology, BC Cancer Agency deal

Champions Oncology (formerly Champions Biotechnology Inc.) exercised its 2010 option for exclusive, worldwide rights to develop and commercialize the agency's cancer candidate Irinophore C. The liposomal formulation of irinotecan is expected to start Phase I testing for advanced solid tumors in 4Q11. The exercise triggers an $85,000...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >